Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.

Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption. J Eur Acad Dermatol Venereol. 2015 Apr; 29(4):767-76.

View in: PubMed

subject areas

Adalimumab
Adult
Anti-Inflammatory Agents, Non-Steroidal
Female
Humans
Male
Middle Aged
Psoriasis
Quality of Life
Recurrence
Retreatment
Severity of Illness Index
Time Factors
Withholding Treatment

authors with profiles

Kenneth Gordon